| Literature DB >> 25838147 |
Thierry Sifferlen1, Amandine Boller1, Audrey Chardonneau1, Emmanuelle Cottreel1, John Gatfield1, Alexander Treiber1, Catherine Roch1, Francois Jenck1, Hamed Aissaoui1, Jodi T Williams1, Christine Brotschi1, Bibia Heidmann1, Romain Siegrist1, Christoph Boss2.
Abstract
Starting from advanced pyrrolidin-2-one lead compounds, this novel series of small-molecule orexin receptor antagonists was further optimized by fine-tuning of the C-3 substitution at the γ-lactam ring. We discuss our design to align in vitro potency with metabolic stability and improved physicochemical/pharmacokinetic properties while avoiding P-glycoprotein-mediated efflux. These investigations led to the identification of the orally active 3-hydroxypyrrolidin-2-one 46, a potent and selective orexin-2 receptor antagonist, that achieved good brain exposure and promoted physiological sleep in rats.Entities:
Keywords: CNS drug discovery; Dual orexin receptor antagonists; Metabolic stability; Orexin receptors; Selective orexin-2 receptor antagonists; Sleep
Mesh:
Substances:
Year: 2015 PMID: 25838147 DOI: 10.1016/j.bmcl.2015.03.035
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823